Low-attenuation Coronary Plaque Volume and Cardiovascular Events in Patients with Distinct Metabolic Phenotypes

Study population and metabolic phenotypes

This study included patients who underwent CCTA between January 2018 and December 2020 and were clinically indicated for stable chest symptoms, along with an abdominal computed tomography (CT) scan to assess abdominal obesity. The exclusion criteria were as follows: (1) acute coronary syndrome; (2) previous history of coronary artery bypass graft or open-heart surgery; (3) congestive heart failure; (4) previous history of percutaneous coronary intervention; (5) insufficient patient information; and (6) loss to follow-up. Figure 1 illustrates the flowchart of the study population comprising 530 patients. All participants provided written informed consent for the use of de-identified data, including clinical information, laboratory tests, and CCTA imaging. The Fujiikai Kashibaseiki Hospital Institutional Review Board approved pooled data analysis (2021-A).

• Download figure
• Open in new tab

Figure 1. Flow chart of study patients

A flowchart depicting the 530 patients who underwent CCTA examination and how they were divided into No-MetS and MetS groups. Patients were further categorized into four groups according to the presence or absence of metabolic equivalents (MetS) and DM. CCTA, coronary computed tomography angiography; DM, diabetes mellitus; MetS, metabolic syndrome.

Non-contrast-enhanced abdominal CT imaging was performed before CCTA to measure the visceral adipose tissue (VAT) areas. VAT areas were measured at the L2–L3 level using a dedicated software (SYNAPSE VINCENT, Fujifilm Inc., Tokyo, Japan). In the present study, abdominal obesity was defined as a VAT area ≥100 cm², corresponding to an abdominal circumference ≥ 85 cm for men and ≥ 90 cm for women ⁹. MetS was defined based on the Japanese Committee for the Diagnostic Criteria of Metabolic Syndrome ¹⁰. MetS was defined as the presence of abdominal obesity with DM (MetS with DM) or two or more of the following components in the absence of DM: (1) systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥85 mmHg; (2) fasting plasma glucose ≥110 mg/dL; and (3) triglycerides ≥150 mg/dL or high-density lipoprotein cholesterol ≤40 mg/dL. In addition, medical therapy using antihypertensive, antidiabetic, and lipid-lowering drugs was considered an MetS component. Patients were further categorized into four groups according to the presence or absence of metabolic equivalents (MetS) and DM. The triglyceride-glucose (TyG) index was used to estimate the insulin resistance in the four groups ¹¹.

Pharmacological treatment and lifestyle modifications were recommended for all patients according to the guidelines for hypertension, dyslipidemia, and diabetes, if present ¹². In addition, patients underwent invasive coronary angiography or coronary revascularization based on the results of the CCTA and noninvasive stress tests ¹³. According to the Japanese Atherothrombosis Society guidelines, the treatment targets of low-density lipoprotein cholesterol (LDL-C) for the primary prevention of ASCVD were <100 mg/dL for high-risk, 120 mg/dL for moderate-risk, or 140 mg/dL for low-risk patients ¹². The treatment target for the fasting triglyceride (TG) level was < 150 mg/dL. For hypertensive patients, the treatment target for blood pressure is <140/90 mmHg, particularly for patients with diabetes or CKD with albuminuria <130/80 mmHg ¹⁴. The target glycemic control was HbA1c < 7.0% for preventing diabetic complications and < 8.0% for those with difficulties in glycemic control for hypoglycemia ¹⁵.

CCTA imaging and analysis

CCTA was performed using a 320-row multi-detector CT scanner (Aquilion ONE/NATURE Edition, Canon Medical Systems, Inc., Japan) ¹⁶. The scan parameters included a detector collimation of 0.5 × 320 mm, gantry rotation time of 350 ms, tube voltage of 120 kV, and tube current of 130–600 mA. An electrocardiogram-triggered prospective gating method was used for CCTA. CACS was evaluated using the Agatston method at a fixed thickness of 3 mm ¹⁷. Images were reconstructed using forward projected model-based iterative reconstruction solution for coronary artery analysis, with a cross-sectional thickness of 0.5 mm and a reconstruction increment of 0.25 mm.

The Agatston score categories were as follows: 0, 1–100, 101–400, and >400 Agatston units, using a software (SYNAPSE VINCENT version 4.6., Fujifilm inc., Tokyo, Japan). Coronary artery diameter stenosis was reported based on a 16-segment American Heart Association model by two observers (K.O. and H.I.). Obstructive CAD was defined as the presence of coronary plaques with diameter stenosis of ≥ 50% in one or more major epicardial vessels, and/or ≥ 50% in the left main coronary segment. Non-obstructive CAD was defined as having less than 50% diameter stenosis of epicardial coronary arteries. Patients who did not fall in either categories were categorized as not having CAD.

For coronary plaque analysis, coronary artery centerlines were identified semi-automatically; the proximal and distal portions of the coronary plaque lesions were manually defined; and the vessel wall, lumen, and plaque components were auto-segmented and manually adjusted. Lesions were categorized based on their composition into calcified plaques (CP) (> 150 Hounsfield units [HU]) and non-CP (NCP) (< 150 HU). Furthermore, a low-attenuation plaque (LAP) was defined as a region with a CT value < 30 HU ¹⁶. The percentage of plaque volume for each component was calculated as the plaque volume divided by the vessel volume.

The epicardial adipose tissue (EAT) volume was measured from contrast-enhanced CT images using the VINCENT software, cited previously ^{16, 18}. Several equidistant axial planes were extracted based on the heart size. The upper limit of the slice was set at the bifurcation of the pulmonary artery trunk, whereas the lower limit was set at the last slice containing any structure of the heart. In each plane, the software autodetected a smooth, closed pericardial contour as the region of interest; adipose tissue was identified with CT attenuation values ranging from -250 to -30 HU within the pericardial sac ^{16, 18}. Finally, EAT volume was calculated as the sum of the EAT areas in each slice. The mean CT value within the measured EAT volume was reported.

Endpoints

The primary endpoint was major adverse cardiovascular events (MACE) defined by a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina, or symptom- or ischemia-driven coronary revascularization. Cardiovascular death was defined as death due to cardiovascular causes including myocardial infarction, sudden cardiac arrest, heart failure, and stroke ¹⁹. Non-fatal myocardial infarction was defined as typical persistent chest pain with elevated cardiac enzymes ¹⁹. Unstable angina was defined as new-onset angina, exacerbation of angina with light exertion, or angina at rest without elevated cardiac enzyme levels. Symptom- or ischemia-driven coronary revascularization was defined as coronary revascularization >3 months after CCTA imaging at baseline, with >75% diameter stenosis with symptoms, or positive functional tests, or with a ≥90% diameter stenosis with symptoms.

Statistical analysis

All statistical analyses were performed using SPSS version 24 software (IBM Corp., Armonk, NY, USA). Categorical variables were presented as absolute and relative frequencies, and continuous variables were presented as mean (±standard deviation). Subject characteristics were compared using one-way analysis of variance for numerical variables. Categorical variables were analyzed using the chi-square or Fisher’s exact tests. Multivariate Cox proportional hazards analysis was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). To test the hypothesis that DM or MetS serve as a predictor of MACE independent of high-risk plaque volume, DM (or MetS) and LAP volume > 4% were entered into the multivariate Cox proportional hazards models adjusted for the Suita CVD risk score (model 1 and model 2). Furthermore, to test the hypothesis that each metabolic phenotype remains as a predictor of MACE independent of high-risk plaque volume, each metabolic phenotype, as compared with non-DM without MetS and LAP volume > 4%, were entered into the multivariate Cox proportional hazards models adjusted for the Suita CVD risk score (models 3, 4, and 5).

Additionally, multivariable models were constructed. Variables entered into the multivariate models were selected on the basis of clinical plausibility, multicollinearity, and known association with CV death and acute coronary syndrome (ACS), with the adjustment for Suita CVD risk score: Model 1, LAP volume > 4% and TyG index; Model 2, LAP volume > 4% and CKD; Model 3, LAP volume > 4% and CRP; and Model 4, LAP volume > 4% and obstructive CAD (any vessels) (supplementary Table 1).

Kaplan–Meier curves and log-rank tests were used to depict and assess the differences in cumulative event rates among the four groups. Analyses were initiated at the time of CCTA imaging and terminated at the earliest occurrence of the primary endpoint or at the median follow-up (2.91 years). Analyses were censored at the last follow-up or at a composite event, whichever occurred earlier. Statistical significance was set at p < 0.05 (two-sided).

Primary outcome

During a mean follow-up period of 2.7 ± 0.9 years (median 2.91 years), MACE was observed in 25 patients (4.7%). The primary outcome was observed in seven patients in the non-MetS without DM group, eight in the non-MetS with DM group, six in the MetS without DM group, and four in the MetS with DM group. The incidence rate for the composite endpoint was highest in the non-MetS with DM group, followed hierarchically by the MetS with DM, MetS without DM, and non-MetS without DM group (p < 0.001, log-rank test; Figure 2).

• Download figure
• Open in new tab

Figure 2. Kaplan–Meier analysis for prediction of MACE stratified by metabolic phenotypes

Kaplan–Meier curves demonstrating significant differences between metabolic phenotypes in cumulative event rates, using a composite endpoint of cardiovascular death, acute coronary syndrome, and symptom- or ischemia-driven coronary revascularization. Higher event rates were present in non-MetS patients with DM (log-rank test, p <0.001), followed by MetS with DM (log-rank test, p <0.001). DM, diabetes mellitus; MetS, metabolic syndrome; MACE, major adverse cardiovascular event.

Table 3 summarizes the unadjusted Cox proportional hazards models used to predict the primary endpoint. CACS > 400 (p < 0.001), LAP volume > 4% (p < 0.001), obstructive CAD (patient-level and vessel-level, p < 0.05), and DM (p < 0.001) were significantly associated with the primary endpoint. Patients with angiographically confirmed MACE (n = 20) exhibited significantly higher prevalence of LAP volume > 4% in LAD (45% versus 23.5%; p = 0.036) and RCA (40% versus 18%; p = 0.035) and tended to have higher prevalence of LAP volume > 4% in LCX (20% vs. 9.3%; p = 0.09) compared to those without MACE. In the multivariable Cox proportional hazards model analysis (Table 4), DM as a predictor was associated with the primary endpoint, independent of LAP volume > 4% (HR for DM in model 1; HR, 2.68; 95% CI, 1.16–6.18; p = 0.02), although MetS did not remain an independent predictor (model 2 in Table 4). For the subgroup analysis of each metabolic phenotype (non-DM without MetS as reference), DM without MetS remained as a predictor of MACE independent of LAP volume > 4% (model 3), whereas DM with MetS (model 4) or non-DM with MetS (model 5) did not reach statistical significance. Finally, we examined the association of MACEs with parameters other than DM or MetS. In the multivariable models, TyG index (HR, 1.78; 95% CI, 1.10–2.89; p = 0.019) or obstructive CAD (HR, 5.49; 95% CI, 1.84–16.38; p = 0.002) was independently associated with MACE even after adjusting for the Suita CVD risk score, but CKD or CRP did not remain as a predictor (supplementary Table 1).

Metabolic disorders, high-risk plaque burden, and outcomes

Several large clinical trials have demonstrated that myocardial ischemia is an important surrogate marker for improving outcomes in patients with stable CAD, whereas ischemia-guided management has a limited ability to prevent acute coronary events compared with optimized medical therapy ^{20, 21}. These findings question the credibility of ischemia-guided management of patients with stable CAD, thus redirecting attention towards coronary microvascular dysfunction and high-risk plaque burden ^22–24. An increased plaque burden, especially of non-calcified plaques, has been reported in patients with MetS ²⁵. Yonetsu et al. used optical coherence tomography to demonstrate that MetS were associated with an increased burden of lipid-rich plaques ²⁵. Although these findings indicate a potential link between obesity, metabolic disorders, and unfavorable coronary plaque features, there is limited knowledge regarding coronary plaque burden in distinct metabolic phenotypes with and without DM.

Previous clinical studies have reported an inverse association between BMI and cardiovascular prognosis (obesity paradox) ^{7, 26, 27}. In patients with ASCVD and DM, Pagidipati et al. demonstrated that overweight or obese individuals had a lower cardiovascular risk than those with normal weight ²⁷. In a sub-analysis of a large clinical CCTA trial of patients with chest pain, among distinct metabolic phenotypes, Kammerlander et al. demonstrated that metabolically unhealthy individuals without obesity exhibited an increased high-risk plaque burden and a high risk of ASCVD events ⁷. This paradoxically benign effect of obesity may be explained by its protective effect against atherosclerosis. Obese patients lack sarcopenia, have limited capacity for exercise, and have reduced mobility, all of which are associated with an increased incidence of cognitive decline, heart failure, and mortality ²⁸. In addition, we observed increased fasting plasma glucose levels in patients with non-MetS DM. Hyperglycemia and insulin resistance have been reported to be key drivers of calcification in DM ^{8, 11, 29}. Liu et al. showed that higher glucose levels and their variability are associated with plaque rupture in patients with ST-segment elevation myocardial infarction ³⁰. These findings suggest that metabolic phenotypes can help identify patients at high risk of cardiovascular events in addition to a high-risk plaque burden.

Epicardial adipose tissue, plaque characteristics, and outcomes

CAD is a chronic inflammatory disease with an underlying risk of metabolic disorders ³¹. A close relationship between abdominal visceral obesity and an increased coronary atherosclerotic burden has been reported ^{4, 32}. Our results demonstrated that MetS patients with or without DM had increased EAT and LAP volumes, whereas non-MetS patients with DM had the worst outcomes, with lower EAT and LAP volumes, indicating an alternate pathophysiology of acute coronary syndromes in the latter. Our findings are consistent with the observations of Kammerlander et al., who demonstrated that both metabolically unhealthy obese and non-obese subjects exhibited increased high-risk plaques ⁷. The increased prevalence of obstructive CAD and vascular calcification (CP) in patients with DM offers a possible explanation for this finding³³. Distinct plaque characteristics may reflect different (advanced or less advanced) stages of coronary atherosclerosis, resulting in different responses to lipid-lowering therapy ³⁴. Furthermore, previous studies investigating plaque structural stress have demonstrated that microcalcifications contribute to increased stress, leading to plaque rupture and myocardial infarction ^{35, 36}. These observations explain the poor outcomes of patients with DM without MetS in this study.

Although we found that the EAT volume was not correlated with outcomes, the mean CT value of the EAT was associated with cardiovascular outcomes (Table 3). EAT has been associated with coronary atherosclerosis, calcification, and cardiovascular outcomes, and has attracted attention as a therapeutic target ^{18, 37–40}. This has motivated the development of imaging methods that enable the assessment of inflammation in the pericoronary adipose tissue, which interacts with the underlying vascular wall by producing proinflammatory adipokines ⁴¹. In a retrospective CCTA study, Oikonomou et al. demonstrated that a fat attenuation index > -70 HU around the epicardial coronary arteries predicts cardiovascular outcomes ⁴². Higher CT attenuation of the EAT indicates an increased inflammatory status, which supports our finding that non-MetS patients with DM have the worst prognosis.

In addition to plaque burden and metabolic disorders, coronary microvascular dysfunction may explain the association between non-MetS patients with DM and poorer outcomes ^{43, 44}. In a systematic analysis, Kelshiker et al. demonstrated that patients with DM were more likely to have impaired coronary microvascular function, which presumably indicates a poor prognosis ⁴⁴. Although the assessment of coronary microvascular dysfunction is appreciated, routine non-invasive evaluation methods are not available in daily clinical practice. Noninvasive assessment of the coronary plaque burden and metabolic phenotypes allows for further risk stratification of symptomatic patients undergoing CCTA.

Study limitations

This study included a relatively small number of patients, and the event rates during follow-up were relatively low (< 5%). Our findings should be interpreted with caution since the DM with MET group was significantly older than the other groups with more obstructive CAD. Further studies are required to confirm these findings. Furthermore, although a unified definition is needed, the criteria for abdominal obesity vary among races ⁴⁵. In the present study, we used quantitative VAT values obtained from CT scans to define abdominal obesity. Lastly, we did not perform laboratory tests such as HOMA-IR to measure insulin resistance, which is associated with inflammation ⁴⁶ and plaque vulnerability ⁸. Instead, we calculated the TyG index and reported its significant association with the primary endpoint, independent of LAP volume > 4% (HR for TyG index, 1.78; 95% CI, 1.10–2.89; p = 0.019) (Model 1, in the supplementary Table 1).